Opulus Lymphoma Precision

by Roche  · Based in Switzerland → — Pioneering personalised healthcare to improve and save lives.
Nuclear Medicine Oncology Radiology

Regulatory Status Disclosed

Overview

Opulus™ Lymphoma Precision is an AI-powered software tool developed by Roche Molecular Systems. It is designed to assist physicians in analyzing whole-body FDG-PET/CT scans of patients already diagnosed with FDG-avid lymphomas. The tool utilizes a machine learning methodology to automate the labor-intensive task of quantifying disease burden.

Key functionalities include the automatic segmentation and visualization of lymphoma lesions, as well as the calculation of the total metabolic tumor volume (TMTV). This supports physicians by reducing manual workload and facilitating more efficient interpretation of PET/CT images. It’s important to note that Opulus™ Lymphoma Precision is an assistive tool; it does not screen for or diagnose lymphoma, and the final clinical decisions remain with the interpreting radiologist. Physicians have the option to accept or reject the output generated by the device.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered software tool for PET/CT analysis
  • Analyzes whole-body FDG-PET/CT scans
  • Automatically segments lymphoma lesions
  • Visualizes lymphoma lesions
  • Calculates total metabolic tumor volume (TMTV)
  • Uses machine learning methodology for lesion localization and segmentation
  • Assists in efficient interpretation of PET/CT images
  • Physician has option to accept/reject output
  • Aids in quantifying disease burden

Use Cases

  • Quantifying disease burden in patients already diagnosed with FDG-avid lymphomas
  • Assisting physicians in the interpretation of FDG-PET/CT images for lymphoma
  • Automating labor-intensive tasks of lesion quantification in PET/CT scans
  • Visualization of suspected lymphoma lesions
  • Calculation of total volume of all lesions in a body

What Physicians Need to Know

Key Capabilities
Opulus™ Lymphoma Precision is an AI-powered software that automates the quantification of disease burden in whole-body FDG-PET/CT scans for patients already diagnosed with FDG-avid lymphomas. It uses machine learning to localize and segment FDG-PET activity (hot-spots) of lymphoma lesions within a PET/CT image, visualize these lesions, and quantify the Total Metabolic Tumor Volume (TMTV). This tool aids medical professionals by automatically generating tumor boundary Regions of Interest (ROIs) and quantifying TMTV, tasks that are tedious when performed manually. The algorithm is assistive and requires review by a radiologist, who makes the final decision on FDG-PET/CT image interpretation. The user can accept or reject the output but cannot modify it.
Clinical Utility
This tool assists trained interpreting physicians with the visualization of suspected lesions and the calculation of the total volume of all lesions in the body. This information can be used in addition to the standard of care image interpretation of FDG-PET/CT scans. It is intended for patients already diagnosed with FDG-avid lymphoma and does not screen for or diagnose lymphoma. The precision of AI-powered diagnostics, like those developed by Roche, can help identify patient populations for therapies that traditional interpretation might miss, potentially validating life-saving treatments. Roche aims to move AI tools from research into routine clinical practice to revolutionize cancer research, diagnostics, and treatment.
Integration Options
Roche is developing an open digital pathology environment to integrate AI tools. The Roche Digital Pathology Open Environment allows software developers to easily integrate their image analysis tools for tissue with Roche's navify® Digital Pathology. This platform facilitates the secure exchange and flow of data, enabling pathologists to access advanced algorithms from third parties alongside Roche's own AI-based image analysis tools. Roche also makes the specifications of its proprietary BIF file format publicly available to encourage the development of reliable image analysis algorithms. Roche's navify® Digital Pathology enterprise software incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation.
Compliance Status
Opulus™ Lymphoma Precision is classified as an Automated Radiological Image Processing Software under regulation number 21 CFR 892.2050, Regulatory Class II, with product codes QIH. Its safety and performance have been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing. It received 510(k) Premarket Notification (K243863) from the FDA.
User Experience
The tool is designed to aid the efficiency of medical professionals by automating tedious tasks like generating tumor boundary Regions of Interest (ROIs) and quantifying TMTV. While the physician has the option to accept or reject the output, they cannot modify it. The algorithm is assistive and requires a radiologist's review for the final decision.
Implementation Complexity
Roche aims to enable rapid adoption of AI tools through its Open Environment, which is designed to break down barriers for technology advances across industry and research partners. Digital pathology solutions from Roche are designed to be flexible, open ecosystems that fit seamlessly within existing workflows and evolve with a lab's digitization needs. Roche provides expertise to support the transition to digital pathology.
Evidence Base
The safety and performance of Opulus™ Lymphoma Precision have been evaluated and verified through software verification and validation testing. Roche emphasizes that its image analysis algorithms are trained using robust and representative data sets to automatically classify cells and provide assay-specific scoring. Studies have shown that image analysis algorithms can enhance pathologist reporting efficiency, with one study demonstrating a 66.8% reduction in diagnostic time. Roche is committed to incorporating ethical principles in its AI development, including mitigating potential biases, safeguarding data privacy, and ensuring information accuracy. Their models are designed with fairness and explainability as paramount considerations.
Physician Tip

Opulus™ Lymphoma Precision is an assistive tool, meaning a radiologist's review is crucial for final interpretation of FDG-PET/CT scans. While the tool automates tedious quantification tasks, the physician retains the ability to accept or reject the generated output. This tool is specifically for patients already diagnosed with FDG-avid lymphoma and should not be used for screening or diagnosis. It can significantly improve efficiency in quantifying disease burden, allowing more focus on complex diagnostic challenges.

Roche is actively fostering an open digital pathology ecosystem, allowing for the integration of third-party AI algorithms with its navify® Digital Pathology software. This means that Opulus™ Lymphoma Precision, or similar future tools, could potentially be used alongside other AI-driven solutions from various developers within a unified workflow. Roche also makes its BIF file format specifications publicly available to encourage further innovation and integration.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Unknown
  • Not ideal for buyers who need public price benchmarks before vendor contact or teams requiring confirmed deployment details before shortlist review
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated

Opulus™ Lymphoma Precision received FDA 510(k) clearance on May 30, 2025. It is a software device that uses a machine learning-based algorithm to automate segmentation and visualization of lesions and calculate total metabolic tumor volume within whole-body FDG-PET/CT scans of patients with FDG-avid lymphomas. It is intended to assist trained interpreting physicians with visualization of suspected lesions and calculation of total volume of all lesions in a body. This information can be used in addition to other clinical information.

Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-05-30K243863 510(k)Opulus™ Lymphoma Precision

What the Web Says

Opulus™ Lymphoma Precision is a software device developed by Roche Molecular Systems, Inc. that utilizes a machine learning-based algorithm to automate the segmentation and visualization of lesions, and to measure total metabolic tumor volume (TMTV) in whole-body FDG-PET/CT scans for patients diagnosed with FDG-avid lymphoma. This tool is designed to assist trained interpreting physicians in visualizing suspected lesions and calculating their total volume, which can be used in conjunction with standard image interpretation. The software aims to improve the efficiency of medical professionals by automating tasks that are otherwise tedious when performed manually.

Overall: Positive

Strengths

  • Automates segmentation and visualization of lesions in FDG-PET/CT scans.
  • Measures total metabolic tumor volume (TMTV) automatically.
  • Aids in the efficiency of medical professionals by automating tedious tasks.
  • Provides information that can be used in addition to standard image interpretation.
  • Raises no new questions of safety or effectiveness according to the FDA.
  • FDA-cleared.

Limitations

  • Does not screen for or diagnose lymphoma.
  • Intended only for patients already diagnosed with FDG-avid lymphoma.
  • The physician has the option to accept/reject the output but cannot modify it.
  • Requires review by a radiologist, who makes the final decision on image interpretation.
  • Limited information available from independent reviews (e.g., Reddit, G2, Capterra).
  • Decision date for FDA clearance is May 30, 2025, suggesting it is a relatively new or upcoming product.

Based on reviews from: parikhradiology.com, fda.gov, healthaidb.com, kpmg.com

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Opulus Lymphoma Precision

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

umed.pl
Opulus™ Lymphoma Precision / Roche. Molecular Systems
Opulus™ Lymphoma Precision by Roche Molecular Systems, approved on May 23, 2025, utilizes AI and machine learning to streamline data analysis and predict new drug structures for more effective treatment.
2025-12
fda.gov
Opulus™ Lymphoma Precision 510(k) Summary
This FDA 510(k) summary details Opulus™ Lymphoma Precision, a software device that uses machine learning to automate segmentation and visualization of lesions, and measurement of total metabolic tumor volume in FDG-PET/CT scans for patients with FDG-avid lymphomas.
2025-05
medtechspectrum.com
AI-Enabled Medical Devices: 100 Most Recent FDA Clearances (2025)
Roche Molecular Systems' Opulus™ Lymphoma Precision was among over 100 AI-enabled medical devices recently authorized by the FDA, reflecting the growing integration of machine learning into healthcare for enhanced diagnostic accuracy and personalized care.
2025-05
fda.gov
Opulus™ Lymphoma Precision
This FDA clearance document lists Roche Molecular Systems, Inc. as the applicant for Opulus™ Lymphoma Precision, classified under regulation number 892.2050 and product code QIH.
2025-05
healthcareaiops.com
Roche Molecular Systems, Inc.: 1 FDA AI clearance
Roche Molecular Systems, Inc. received one FDA AI clearance for Opulus™ Lymphoma Precision on May 30, 2025, with the product code QIH.
2025-05
fda.report
Opulus™ Lymphoma Precision, Roche Molecular Systems, Inc.
Opulus™ Lymphoma Precision, developed by Roche Molecular Systems, Inc., received FDA clearance on May 30, 2025, under product code QIH.
2026-05
innolitics.com
Ground Truth in AI/ML SaMD: The Fastest Path to a Defensible Submission
The article references Opulus™ Lymphoma Precision (K243863, Roche Molecular Systems, Inc.) in the context of establishing 'ground truth' for medical device submissions, noting that the reference standard was based on three radiologists/nuclear medicine physicians with expertise in interpreting PET/CT scans from patients with FDG-avid lymphoma.
2025-09

Videos

Product demos, reviews, and walkthroughs for Opulus Lymphoma Precision.

Loading videos...

View all on YouTube

Frequently Asked Questions

Opulus™ Lymphoma Precision is a software device that uses machine learning to automate the segmentation and visualization of lesions, as well as the measurement of total metabolic tumor volume within whole-body FDG-PET/CT scans for patients with FDG-avid lymphomas. It assists trained physicians by localizing and segmenting FDG-PET activity, thereby quantifying disease burden, but it does not screen for or diagnose lymphoma.
Opulus™ Lymphoma Precision is a Class II medical device regulated under 21 CFR 892.2050, classified as Automated Radiological Image Processing Software. It received 510(k) clearance from the FDA. The device is intended to be used in addition to standard-of-care image interpretation, and its annotated images must be reviewed by an appropriately trained physician, as the algorithm is assistive and requires radiologist review for final decisions.
While AI tools offer promising results, many are still in preclinical studies or small clinical trials, necessitating larger, multi-center prospective trials for validation. Potential issues with AI-powered models include under-fitting or over-fitting, which can occur if the algorithm is inadequately trained or lacks relevant predictive features. The user also does not have the ability to modify the device output, only to accept or reject it.
Traditional methods for assessing lymphoma include histopathological subtyping and various genetic analyses like GWAS and NGS, which identify biomarkers and mutations. Other diagnostic aids, such as Roche's VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, help differentiate B-cell lymphoma from reactive immune responses. Opulus™ Lymphoma Precision specifically focuses on automating the quantification of disease burden from FDG-PET/CT scans, a task that is labor-intensive when performed manually.
Opulus™ Lymphoma Precision is designed to aid the efficiency of medical professionals by automatically generating tumor boundary Regions of Interest (ROIs) and quantifying Total Metabolic Tumor Volume (TMTV). Physicians have the option to accept or reject the output generated by the device, but cannot modify it. The annotated images require review by a trained physician, who makes the final decision on FDG-PET/CT image interpretation.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-12 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.